Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Thursday, December 04, 2025Eli Lilly and Company today announced that the US Food and Drug Administration FDA has granted approval to Jaypirca pirtobrutinib mg mg tablets for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Wednesday, December 03, 2025AstraZenecas New Drug Application NDA for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration FDA in the US for the treatment of adult patients with hardtocontrol
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Tuesday, December 02, 2025Sandoz the global leader in affordable medicines today announced the European launch of Wyost denosumab mg and Jubbonti denosumab mg The medicines are among the first denosumab biosimilars to launch
Zentiva Expands into Biologics with the EU-Wide Launch of Its First Biosimilar
Tuesday, December 02, 2025Zentiva a leading European manufacturer of affordable highquality medicines today announced the first EUwide launch of a monoclonal antibody biosimilar following approval by the European Medicines Agency EMA
EXmoor Pharma and Royal Free London launch strategic collaboration to strengthen UK cell and gene therapy manufacturing pathway
Thursday, November 27, 2025EXmoor Pharma the integrated cell and gene therapy CDMO with embedded consultancy expertise and Royal Free London NHS Foundation Trust through its Cell and Vector Innovation Centre CVIC
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
Wednesday, November 26, 2025Otsuka Pharmaceutical Co Ltd Otsuka and Otsuka Pharmaceutical Development Commercialization Inc announce the filing of a New Drug Application NDA with the US Food and Drug Administration FDA for centanafadine
Mettler-Toledo Launches X3 Series to Transform Bulk Flow Inspection with Advanced Detection, Hygienic Design and Precision Rejects
Tuesday, November 25, 2025MettlerToledo Product Inspection has unveiled the new X Series of bulk flow xray inspection systems designed to deliver classleading physical contamination detection precision waste reduction and simplified operation
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Friday, November 21, 2025Bayer announced today that the US Food and Drug Administration FDA has approved HYRNUO sevabertinib an oral reversible tyrosine kinase inhibitor TKI for the treatment of adult patients with locally advanced or metastatic nonsquamous nonsmall cell lun...
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer
Friday, November 21, 2025Thermo Fisher Scientific the world leader in serving science has received approval from the US Food and Drug Administration FDA for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic CDx to identify patients who may be eligible for tre...
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
Tuesday, November 18, 2025OmniAb Incand ArrowMark Partners ArrowMark today announced the signing of a license and services agreement for novel OmniAbderived antibody discovery programs with Mabtrx Biosciences
